Trends in prostate cancer survival in Spain: Results from population-based cancer registries

Clinical and Translational Oncology

Volumn 14, Issue 6, 2012, Pages 458-464

  Marcos Gragera, Rafael ^a,b,e   Salmerón, Diego ^b,c,d   Izarzugaza, Isabel ^f   Ardanaz, Eva ^b,g   Serdà, Bernat Carles ^e   Larrañaga, Nerea ^b,h   San Román, Erkuden ^g   Navarro, Carmen ^b,c,d   Chirlaque, María Dolores ^b,d  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c UNIVERSITY OF MURCIA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e UNIVERSITY OF GIRONA   (Spain)

^f Servicio de Prestaciones Farmacéuticas   (Spain)

^g INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^h Subdirección de Salud Pública de Gipuzkoa ^*  (Spain)

Author keywords

Incidence; Prostate cancer; PSA; Quality of life; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER SCREENING; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POISSON DISTRIBUTION; PROSTATE CANCER; REGRESSION ANALYSIS; SPAIN; TREND STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REGISTRIES; RISK; SPAIN; SURVIVAL ANALYSIS;

EID: 84864691000     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0824-0     Document Type: Article

References (50)

1. Hankey BF, Feuer EJ, Clegg LX et al (1999) Cancer surveillance series: interpreting trends in prostate cancer part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91:1017-1024
2. Kvale R, Auvinen A, Adami HO et al (2007) Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst 99:1881-1887
3. Larranaga N, Galceran J, Ardanaz E et al (2010) Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol 21[Suppl 3]:iii83-iii89
4. Potosky AL, Miller BA, Albertsen PC, Kramer BS (1995) The role of increasing detection in the rising incidence of prostate cancer. JAMA 273:548-552
5. Brenner H, Arndt V (2005) Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: populationbased estimates for the year 2000 by period analysis. J Clin Oncol 23:441-447
6. Borras J, Marcos-Gragera R, Torres A, Espinas JA (2008) [Analysis of cancer incidence, survival and mortality according to the main tumoral localizations, 1985-2019: prostate cancer]. Med Clin (Barc) 131[Suppl 1]:63-66
7. Galceran J, Puigdefabregas A, Ribas G et al (2008) Cancer survival trends in Catalonia and comparison with Europe. Med Clin (Barc) 131[Suppl 1]:19-24
8. Etzioni R, Penson DF, Legler JM et al (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94:981-990
9. Merrill RM, Wiggins CL (2002) Incidental detection of population-based prostate cancer incidence rates through transurethral resection of the prostate. Urol Oncol 7:213-219
10. Baade PD, Youlden DR, Krnjacki LJ (2009) International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res 53:171-184
11. Collin SM, Martin RM, Metcalfe C et al (2008) Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 9: 445-452
12. Bray F, Lortet-Tieulent J, Ferlay J et al (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46:3040-3052
13. Cayuela A, Rodriguez-Dominguez S, Martin VE, Candau BR (2008) Recent changes in prostate cancer mortality in Spain. Trends analysis from 1991 to 2005. Actas Urol Esp 32:184-189
14. Verdecchia A, Guzzinati S, Francisci S et al (2009) Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer 45:1042-1066
15. Chirlaque MD, Salmeron D, Ardanaz E et al (2010) Cancer survival in Spain: estimate for nine major cancers. Ann Oncol 21[Suppl 3]:iii21-iii29
16. Curado MP, Edwards B, Shin HR et al (eds) (2007) Cancer incidence in five continents, vol. IX. IARC, Lyon
17. Navarro C, Martos C, Ardanaz E et al (2010) Population-based cancer registries in Spain and their role in cancer control. Ann Oncol 21[Suppl 3]:iii3-13
18. Martos MC, Saurina C, Feja C et al (2009) Accurately estimating breast cancer survival in Spain: cross-matching local cancer registries with the National Death Index. Rev Panam Salud Publica 26:51-54
19. Navarro C (2006) The National Death Index: a largely expected advance in the access to mortality data. Gac Sanit 20:421-423
20. Ferlay J, Burkhard S, Whelan S, Parkin DM (2005) Check and conversion programs for cancer registries (IARC/IACR Tools for Cancer Registries in Europe). IARC, Lyon
21. de Angelis R, Francisci S, Baili P et al (2009) The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. Eur J Cancer 45:909-930
22. Frit A, Jack A, Percy C et al (2000) International Classification of Diseases for Oncology, 3rd edn. World Health Organisation, Geneva
23. Cancer Survival Group (2011) Strel Computer Program Version V 6.0 for Cancer Survival Analysis. (7 June 2011, date last accessed)
24. Esteve J, Benhamou E, Croasdale M, Raymond L (1990) Relative survival and the estimation of net survival: elements for further discussion. Stat Med 9:529-538
25. Corazziari I, Quinn M, Capocaccia R (2004) Standard cancer patient population for age standardizing survival ratios. Eur J Cancer 40:2307-2316
26. Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51-64
27. Anonymous (2007) StataCorp. Stata Statistical Software: Release 10. StataCorp LP, TX
28. Sanchez MJ, Payer T, De Angelis R et al (2010) Cancer incidence and mortality in Spain: estimates and projections for the period 1981-2012. Ann Oncol 21[Suppl 3]:iii30-iii36
29. Welch HG, Schwartz LM, Woloshin S (2000) Are increasing 5-year survival rates evidence of success against cancer? JAMA 283:2975-2978
30. Draisma G, Etzioni R, Tsodikov A et al (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101:374-383
31. Coleman MP, Quaresma M, Berrino F et al (2008) Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9:730-756
32. Jonler M, Eddy B, Poulsen J (2005) Prostatespecific antigen testing in general practice: a survey among 325 general practitioners in Denmark. Scand J Urol Nephrol 39:214-218
33. Andren O, Garmo H, Mucci L et al (2009) Incidence and mortality of incidental prostate cancer: a Swedish register-based study. Br J Cancer 100:170-173
34. Bangma CH, Roemeling S, Schroder FH (2007) Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 25:3-9
35. Flamand V, Zini L, Salleron J et al (2008) Observational survey on variations of prostate cancer incidence by stage in the Nord-Pas-de-Calais region between 1998 and 2004. Prog Urol 18:53-59
36. Vutuc C, Waldhoer T, Madersbacher S et al (2001) Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality. Eur J Cancer Prev 10:425-428
37. Sandblom G, Varenhorst E, Rosell J et al (2011) Randomised prostate cancer screening trial: 20 year follow-up. BMJ 342:d1539
38. Pashayan N, Duffy SW, Pharoah P et al (2009) Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer 100:1198-1204
39. Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328
40. Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101:1325-1329
41. Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Goteborg randomized population-based prostate-cancer screening trial. Lancet Oncol 11:725-732
42. Harlan LC, Potosky A, Gilliland FD et al (2001) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93:1864-1871
43. van Leeuwen PJ, Connolly D, Gavin A et al (2010) Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer 46:377-383
44. Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102:605-613
45. Namiki S, Arai Y (2010) Health-related quality of life in men with localized prostate cancer. Int J Urol 17:125-138
46. Ponholzer A, Brossner C, Struhal G et al (2006) Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World J Urol 24:325-330
47. Voerman B, Fischer M, Visser A et al (2006) Health-related quality of life in Dutch men with prostate cancer. J Psychosoc Oncol 24:49-64
48. Johansson JE, Andren O, Andersson SO et al (2004) Natural history of early, localized prostate cancer. JAMA 291:2713-2719
49. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101
50. Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302:1685-1692